Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer

Objectives: PSMA (prostate-specific membrane antigen) is overexpressed in prostate cancer cells and is reported to be a promising target for antibody-based radioligand therapy in patients with metastasized prostate cancer. Since PSMA expression is not restricted to prostate cancer, the underlying st...

Authors: Schmidt, Lars Henning
Heitkötter, Birthe Franziska
Schulze, Arik Bernard
Schliemann, Christoph
Steinestel, Konrad Ernst
Trautmann, Marcel
Marra, Alessandro
Hillejan, Ludger
Mohr, Michael
Evers, Georg Heribert
Wardelmann, Eva
Rahbar, Kambiz
Görlich, Dennis
Lenz, Georg
Berdel, Wolfgang E.
Hartmann, Wolfgang
Wiewrodt, Rainer Gerhard
Huss, Sebastian
Division/Institute:FB 05: Medizinische Fakultät
Document types:Article
Media types:Text
Publication date:2017
Date of publication on miami:21.03.2019
Modification date:22.06.2022
Edition statement:[Electronic ed.]
Source:PLoS ONE 12 (2017) 10, e0188262, 1-12
DDC Subject:610: Medizin und Gesundheit
License:CC BY 4.0
Language:English
Funding:Finanziert durch den Open-Access-Publikationsfonds 2018 der Deutschen Forschungsgemeinschaft (DFG) und der Westfälischen Wilhelms-Universität Münster (WWU Münster).
Format:PDF document
URN:urn:nbn:de:hbz:6-45159558749
Other Identifiers:DOI: 10.1371/journal.pone.0186280
Permalink:https://nbn-resolving.de/urn:nbn:de:hbz:6-45159558749
Digital documents:artikel_schmidt_2017.pdf

Objectives: PSMA (prostate-specific membrane antigen) is overexpressed in prostate cancer cells and is reported to be a promising target for antibody-based radioligand therapy in patients with metastasized prostate cancer. Since PSMA expression is not restricted to prostate cancer, the underlying study investigates PSMA expression in non-small cell lung cancer (NSCLC). Material and methods: Immunohistochemistry was used to identify PSMA expression in n = 275 samples of NSCLC tissue specimens. By means of CD34 co-expression, the level of PSMA expression in tumor associated neovasculature was investigated. The impact of PSMA expression on clinicopathologic parameters and prognosis was evaluated. Results: PSMA tumor cell expression in NSCLC is as low as 6% and was predominantly found in squamous cell carcinoma (p = 0.002). Neovascular PSMA expression was found in 49% of NSCLC. High neovascular PSMA expression was associated with higher tumor grading (G3/G4) (p < 0.001). Neither for PSMA tumor cell expression, nor for PSMA neovascular cell expression prognostic effects were found for the investigated NSCLC cases. Conclusion: Here, we report on the expression of PSMA in NSCLC tissue samples. Against the background of a potential treatment with radiolabeled PSMA ligands, our data might serve for the future identification of patients who could benefit from this therapeutic option.